Shares of Opko Health Inc. (NYSE:OPK) ended Tuesday session in red amid volatile trading. The shares closed down -0.12 points or -1.15% at $10.28 with 4,621,334 shares getting traded. Post opening the session at $10.22, the shares hit an intraday low of $10.20 and an intraday high of $10.44 and the price vacillated in this range throughout the day. The company has a market cap of $5.61 billion and the numbers of outstanding shares have been calculated to be 545.84 million shares.
Opko Health Inc. (OPK) on March 28, 2016 announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals.
Prior to joining OPKO, Ron held senior regulatory positions at Allergan (through its acquisition of Durata Therapeutics), spent over 16 years at Pfizer in various regulatory affairs positions, and most recently worked as an independent consultant providing strategic regulatory consulting services to the pharmaceutical industry. Ron received his PhD in organic chemistry from the California Institute of Technology and he also holds a Masters in Business Administration from Fairleigh Dickinson University.
“Ron has over 40 years of pharmaceutical industry development experience, including over 30 years in regulatory affairs, safety/risk management and quality assurance, which will be of tremendous value as we continue to bring our product candidates to market,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.
Shares of Brookdale Senior Living, Inc. (NYSE:BKD) ended Tuesday session in red amid volatile trading. The shares closed down -0.46 points or -2.83% at $15.79 with 4,372,989 shares getting traded. Post opening the session at $16.05, the shares hit an intraday low of $15.77 and an intraday high of $16.25 and the price vacillated in this range throughout the day. The company has a market cap of $3.03 billion and the numbers of outstanding shares have been calculated to be 184.89 million shares.
Brookdale Senior Living, Inc. (BKD) on March 1, 2016 announced that Mark Ohlendorf, the Company’s President, will step down effective March 18, 2016, and that Kristin Ferge, the Company’s Executive Vice President and former Chief Accounting Officer and Treasurer, will step down effective March 11, 2016. Upon the effective date of Mr. Ohlendorf’s departure from the Company, Andy Smith, Brookdale’s CEO, will assume the role of President and Chief Executive Officer.
Mr. Smith said, “As we’ve worked through the transition process following the hiring of Labeed Diab as our new Chief Operating Officer and Cindy Baier as our new Chief Financial Officer late last year, we have continued to refine our thinking regarding the organizational structure necessary to position us for future growth and success. As a result of that review, we have determined that it is best to move most of the functions currently reporting to Mark and Kristin to the organizations headed by Labeed and Cindy.”
Mr. Diab will assume oversight of the Company’s service alignment and owner relations functions, and Ms. Baier will assume oversight of the Company’s pricing, revenue cycle management and analytics initiatives. Mr. Smith will assume oversight of the Company’s corporate development function and strategy and innovation initiatives.
Mr. Ohlendorf has served in a variety of executive leadership roles for Brookdale and one of its predecessor companies since 1997, including service as Brookdale’s Chief Financial Officer from March 2007 until November 2015. Ms. Ferge joined one of Brookdale’s predecessors in 1998 and has served as an Executive Vice President of Brookdale since August 2005 and as Chief Accounting Officer from July 2014 through January 2016.
“On behalf of our Board and everyone at Brookdale, I want to express our sincere thanks to Mark and Kristin for their tremendous leadership over the years” said Mr. Smith. “They are talented and dedicated leaders who have made many valuable contributions to our company, and we wish them all the best.”
Shares of CVS Health Corp (NYSE:CVS) ended Tuesday session in red amid volatile trading. The shares closed down -1.32 points or -1.26% at $103.16 with 4,367,604 shares getting traded. Post opening the session at $104.03, the shares hit an intraday low of $102.95 and an intraday high of $104.21 and the price vacillated in this range throughout the day. The company has a market cap of $112.95 billion and the numbers of outstanding shares have been calculated to be 1.10 billion shares.
CVS Health Corp (CVS) on April 5, 2016 announced that CVS Specialty, the company’s specialty pharmacy, has been awarded Specialty Pharmacy accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
“Receiving accreditation from URAC demonstrates our commitment to providing high-quality care to patients served by CVS Specialty,” said Alan Lotvin, MD Executive Vice President, CVS Health and President, CVS Specialty. “At CVS Specialty, we are focused on providing quality care that supports the whole patient throughout their treatment journey. We not only make it easier and more convenient for patients to get started on a specialty therapy, but our expert clinicians also provide clinical support and insurance guidance. As a result, patients are more likely to take their specialty medicine as prescribed and also report high satisfaction with the service they receive.”
Specialty pharmacies generally serve patients with complex conditions, including rheumatoid arthritis and multiple sclerosis, who take medications that sometimes require special handling. Specialty pharmacies often also provide care coordination, disease education and 24/7 access to patient support. The URAC accreditation program for Specialty Pharmacy evaluates organizational standards, including pharmacy care; customer service, communications, and disclosure standards; specialty drug and patient management; and pharmacy operations.
“We applaud CVS Health on achieving URAC Specialty Pharmacy Accreditation,” said URAC President and CEO Kylanne Green. “In today’s healthcare market, URAC accreditation provides a mark of distinction for organizations to demonstrate their commitment to quality healthcare.”